Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Véronique Loustaud-Ratti

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
The Lancet. Infectious Diseases|March 17, 2015
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)Marc Bourlière, Jean-Pierre Bronowicki, Victor de Ledinghen, et al.
BMC Infectious Diseases|April 4, 2019
Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohortAnne Laurain, Sophie Metivier, Georges Haour, et al.
BMC Gastroenterology|September 11, 2023
International survey among hepatologists and pulmonologists on the hepatic hydrothorax: plea for recommendationsJean-François David Cadranel, Isabelle Ollivier-Hourmand, Jacques Cadranel, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 4, 2025
Real-World Outcomes of Atezolizumab-Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF CohortManon Allaire, Elhadji Malick Thiam, Guiliana Amaddeo, et al.
Journal of Hepatology|September 14, 2016
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patientsStanislas Pol, Marc Bourliere, Sandy Lucier, et al.
Viruses|April 27, 2026
Delta Describe, the French Collaborative Project: The Profile and Management of Hepatitis Delta Patients in Metropolitan FranceMarie Bosselut, Paul Carrier, Ségolène Brichler, et al.
European Journal of Gastroenterology & Hepatology|August 13, 2025
Real-life data on hepatocellular carcinoma in the French prospective CHIEF cohort in the era of immunotherapyEric Nguyen-Khac, Philippe Merle, Hajer Ben Khadhra, et al.
BMC Infectious Diseases|January 28, 2022
Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosisGeorges-Philippe Pageaux, Clovis Lusivika Nzinga, Nathalie Ganne, et al.
Lancet (London, England)|February 16, 2019
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort studyFabrice Carrat, Hélène Fontaine, Céline Dorival, et al.
Journal of Hepatology|February 28, 2025
Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosisPierre Nahon, Clovis Lusivika-Nzinga, Philippe Merle, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
The Lancet. Infectious Diseases|March 17, 2015
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)Marc Bourlière, Jean-Pierre Bronowicki, Victor de Ledinghen, et al.
BMC Infectious Diseases|April 4, 2019
Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohortAnne Laurain, Sophie Metivier, Georges Haour, et al.
BMC Gastroenterology|September 11, 2023
International survey among hepatologists and pulmonologists on the hepatic hydrothorax: plea for recommendationsJean-François David Cadranel, Isabelle Ollivier-Hourmand, Jacques Cadranel, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 4, 2025
Real-World Outcomes of Atezolizumab-Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF CohortManon Allaire, Elhadji Malick Thiam, Guiliana Amaddeo, et al.
Journal of Hepatology|September 14, 2016
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patientsStanislas Pol, Marc Bourliere, Sandy Lucier, et al.
Viruses|April 27, 2026
Delta Describe, the French Collaborative Project: The Profile and Management of Hepatitis Delta Patients in Metropolitan FranceMarie Bosselut, Paul Carrier, Ségolène Brichler, et al.
European Journal of Gastroenterology & Hepatology|August 13, 2025
Real-life data on hepatocellular carcinoma in the French prospective CHIEF cohort in the era of immunotherapyEric Nguyen-Khac, Philippe Merle, Hajer Ben Khadhra, et al.
BMC Infectious Diseases|January 28, 2022
Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosisGeorges-Philippe Pageaux, Clovis Lusivika Nzinga, Nathalie Ganne, et al.
Lancet (London, England)|February 16, 2019
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort studyFabrice Carrat, Hélène Fontaine, Céline Dorival, et al.
Journal of Hepatology|February 28, 2025
Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosisPierre Nahon, Clovis Lusivika-Nzinga, Philippe Merle, et al.
Pageof 8